Genprex, Inc. announced that through its collaboration agreement with a large network of integrated, community-based oncology practices, the Company has added multiple clinical trial sites for its Acclaim-3 clinical study of Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) in combination with Genentech's Tecentriq (atezolizumab) to treat patients with extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is an aggressive form of lung cancer that is presently incurable. Preclinical studies in mice support the hypothesis that re-expressing the TUSC2 protein may lead to improved clinical efficacy in combination with Tecentriq.

About the Acclaim-3 Clinical Trial The Acclaim-3 clinical trial is a Phase 1/2 open-label, dose escalation and clinical response study of maintenance therapy evaluating Reqorsa in combination with TecentriQ in patients with ES-SCLC. The Acc Acclaim-3 clinical trial will enroll patients who did not develop tumor progression after receiving Tecentriq and chemotherapy as standard initial treatment, and who are therefore eligible for maintenance therapy. The Phase 1 dose escalation portion of the Acclaim-3 clinical study was initially expected to enroll up to 12 patients at three to five U.S. clinical sites, which has now doubled to approximately 10 U.S. clinical sites., to determine the Maximum Tolerated Dose (MTD).

Genprex has received U.S. Food and Drug Administration (FDA) Ophran Drug and Fast Track designations for the Acclaim-3 patient population. Additional information about the Acclaim-3 clinical trial can be found by visiting ClinicalTrials.gov. The Company's lead product candidate, Reqorsa immunogene Therapy (quaratusUGene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; and the Company's lead product candidate, reqorsa Immunogen Therapy (quaratusugen ozeplasmid), are being evaluated in three clinical trials As a treatment for NSCLC. Each of Gen preclinical studies has received a Fast Track Designations from the FDA for the treatment the treatment of that patient population.

Each of Genprex' three lung cancer clinical programs has receive a Fast Track Designation from The FDA for the treatment of that patients in need and Genprex's S CLC program has received an FDAOrphan Drug Designation. such statements include, but are notlimited to, statements regarding: Gen preprex's ability to advance The clinical development, manufacturing and commercialisation of its product candidates in accordance With projected timelines and specifications; the timeline and success of Genprex' clinical trials and regulatory approvals; the timing and approval of Genprex's Phase 1 clinical trial will enroll patients who were not limited to, statements regarding the Acclaim-3 clinical trials.